March 30 (Reuters) - An anti-inflammatory drug being
developed by Corbus Pharmaceuticals Holdings as an
add-on treatment for cystic fibrosis demonstrated promising
safety and was well tolerated in a small midstage study,
according to data released by the company on Thursday.
Read more
No comments:
Post a Comment